The Latest Breaking News from BofA Securities

The Section 201 Solar tariffs on bifacial panels will probably not be extended, which could potentially erode First Solar, Inc’s (NASDAQ: FSLR) pricing power, according to BofA Securities.

While Ameresco Inc.’s (NYSE: AMRC) shares are down due to the disappointing BBB legislative and rates, as well as leverage factors and concerns around its delayed Analyst Day, according to BofA Securities the company offers “superior EBITDA growth (high-teens)” and the potential of a po

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.

Carnival Corp (NYSE:CCL) has extended its share purchase program until April 30, 2022, under the same terms, from the previous date of January 31, 2022. The company had offered to sell shares of its common stock through its agent BofA Securities, having an aggregate offering price of up to $500 million. As announced…

Crescent Capital BDC Inc (NASDAQ: CCAP) has been gaining share in the middle market, where demand for capital “remains robust,” according to BofA Securities.

Ginkgo Bioworks Holdings Inc (NYSE: DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.

Although expectations in the automotive industry have been “set reasonably low” heading into the quarter, investors are likely to focus on outlooks for 2022 and beyond, according to BofA Securities.

The underlying fundamentals in the airline sector remain challenging. Against this backdrop, investors should focus on quality names such as Delta Air Lines, Inc.

Although Blue Owl Capital Inc.’s (NYSE: OWL) stock has been underperforming, the company enjoys a high-growth, high-margin and capital-light business, according to BofA Securities.

Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ: INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities.

There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.